On Monday, Indian food safety watchdog the Food Safety and Standards Authority of India (FSSAI) announced that health supplements cannot be sold as medicines at all and also fixed the permissible limits of various ingredients used in the products. New standards have been issued for manufacturers of the products to check mislabelling.
The Food Safety and Standards Authority of India has operationalised with immediate effect new standards for 8 categories of products including health supplements and nutraceuticals.
CEO Pawan Aggarwal said “Last year, we had issued draft standards on health supplements, nutraceuticals, food for special dietary use, food for special medical purpose, functional food and novel food. We have finalized this and operationalised with immediate effect,”
The Food Safety and Standards Authority of India (FSSAI) will now start granting licences and approve products manufactured based on the new standards. However, these regulations will be enforced from January 2018. “Considering that the regulation is final, FSSAI has made the regulations operational with immediate effect in order to facilitate food business,” the regulator said in a statement.
The new rules comprises of the following,
- Every package of health supplement should carry the words ‘health supplement’ as well as an advisory warning ‘not for medicinal use’ prominently written.
- “The quantity of nutrients added to the articles of food shall not exceed the recommended daily allowance as specified by the Indian Council of Medical Research and in case such standards are not specified, standards laid down by the international food standards body namely Codex Alimentarius Commission shall apply,”
- Health supplements may be used to supplement the normal diet of anyone above the age of 5 years.
- Labelling and packaging norms have been prescribed for nutraceuticals, food for special dietary use, food for special medical purpose, functional and novel food.
Confederation of Indian Industry (CII) said the regulation will help greatly in resolving the issues challenges this sector and creating a conducive regulatory environment for the industry to operate.
Other News
Imports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
TGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More
